Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Regeneron Pharmaceuticals Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.09 (market cap $77.37B), while Regeneron Pharmaceuticals Inc trades at $672.4 (market cap $70.47B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock and Regeneron Pharmaceuticals Inc are close in size by market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| MDLZ | REGN | |
|---|---|---|
Market Cap | $77.37B | $70.47B |
Sector | Consumer Staples | Health |
52-Week High | $70.75 | $812.27 |
52-Week Low | $51.51 | $545.46 |
Enterprise Value | $97.46B | $64.42B |
Dividend Yield | 3.32% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $60.15, down 1.39% today, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 28.77% gross margins and has beaten earnings estimates for three consecutive quarters. Recent corporate developments include a new CFO appointment and continued dividend payments, while analyst consensus remains strongly positive with a $68 price target representing 13% upside potential.
The outlook for MDLZ appears favorable with consistent earnings beats and solid dividend yield, though investors face risks from margin compression and commodity price volatility. Wall Street's bullish stance is supported by the company's market leadership in snacks and innovation pipeline, but execution on volume growth remains critical for sustained performance.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
